Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.30.2 (
endonuclease
)
18,621
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Canavan disease (CD), an autosomal recessive neurodegenerative disorder, is caused by mutations in the
aspartoacylase
(
ASPA
) gene. In the present study, the
ASPA
gene was analyzed in 24 non-Jewish patients with CD from 23 unrelated families. Within this cohort, we found three large novel deletions of approximate 92, 56, and 12.13 kb in length, using both self-ligation of restriction
endonuclease
-digested DNA fragments with long-distance inverse PCR and multiplex dosage quantitative PCR analysis of genomic DNA. The 92 kb large deletion results in complete absence of the
ASPA
gene in one homozygous and one compound heterozygous patient, respectively. The 56 kb large deletion causes absence of the majority of the
ASPA
gene except for exon 1 alone in a compound heterozygous patient. The 12.13 kb deletion involves deletion of the
ASPA
gene from intron 3 to intron 5 including exons 4 and 5 (I3 to E4E5I5) in a compound heterozygous patient. Patients with the three large deletions clinically manifested severe symptoms at birth, including seizures. Our study showed that the combined use of long-distance inverse PCR and multiplex dosage quantitative PCR analysis of genomic DNA is a helpful and rapid technique to search for large deletions, particularly for detection of large deletions in compound heterozygous patients.
...
PMID:Rapid detection of three large novel deletions of the aspartoacylase gene in non-Jewish patients with Canavan disease. 1685 7